SWISSTO12
Inmarsat, a world leader in global, mobile satellite communications, has announced that SWISSto12, one of Europe’s fastest growing aerospace providers, will develop its new eighth-generation of spacecraft. The three I-8 satellites will provide additional network resilience, securing the future of Inmarsat’s global L-band safety services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005018/en/
An illustration of SWISSto12's HummingSat in geostationary orbit. Image credit: SWISSto12
SWISSto12, headquartered in Switzerland, will use its HummingSat satellite platform - in conjunction with unique 3D-printing technologies and specialised Radio-Frequency (RF) and payload products - to develop and manufacture the geostationary satellites, which will launch by 2026.
Just 1.5 cubic metres in volume, the I-8’s will use SWISSto12’s innovative new class of spacecraft which has a form factor up to five times smaller than conventional geostationary satellites yet can still deliver critical safety services with certainty.
The three l-8 satellites will continue to provide the extra layer of resilience to complement the existing constellation and Inmarsat’s two I-6 generation satellites, which were launched in December 2021 and February 2023. In March 2023, Inmarsat announced the first, I-6 F1, had successfully completed testing with ground stations in Western Australia and has now started to provide Ka-band services for the fast-growing Asia Pacific region. The company will begin introducing its L-band capacity and transitioning services to the new satellite throughout 2023.
The second, I-6 F2, which launched in February 2023, is expected to enter operational service over Europe, Africa, and much of the Americas in early 2024.
Each I-8 will also extend Inmarsat’s history of launching and operating radionavigation transponders for Governments and international space agencies. These transponders can enable Satellite-Based Augmentation System (SBAS) services around the world, for example for air traffic controllers or coastguards. SBAS systems uses satellite connectivity, land-based infrastructure, and software to enhance standard GPS/Galileo accuracy of 5 to 10 metres to as little as just 10cm.
Such precise tracking could enable pinpoint safety navigation on aircraft, help emergency services reach vessels in distress more quickly, or allow a raft of industrial innovations, like device tracking in agriculture or advanced, automated transport management systems.
The I-8 satellites will continue to secure Inmarsat’s global safety services into the 2040’s. The company was founded in 1979 under the auspices of the United Nations specifically to provide highly reliable safety communications. Today some 1.6 million seafarers and over 200 airlines rely on Inmarsat’s global L-band network to deliver 99.9% availability every day.
The Inmarsat-8 programme forms part of Inmarsat’s fully-funded technology roadmap, which will include five new satellite payloads added by 2025 to further Inmarsat’s high-speed broadband Global Xpress (GX) network with the launch of the software defined satellites GX 7,8, and 9, aimed for 2025, and the polar coverage satellites GX10a and b, which are aimed for the first half of 2024.
Peter Hadinger, Chief Technology Officer, Inmarsat, said “Every single day people around the world depend on Inmarsat services. Our customers have demanding, and often safety critical, missions that rely on our satellite technology for links that can make the difference. The I-8’s will not only underpin our existing capabilities for the future; but enable ever more advanced safety innovations like SBAS that can ultimately help save more lives. We have chosen SWISSto12 because they have the ground-breaking technology that can make it a reality.”
Emile de Rijk, CEO, SWISSto12, said “We are delighted that Inmarsat has selected SWISSto12 as its partner for its landmark l-8 program. It demonstrates that, with HummingSat, we have created a highly-advanced new class of small geostationary spacecraft that delivers world-leading connectivity capabilities at a fraction of the cost. Our proprietary 3D-printing of Radio Frequency payload technology allows us to push the limits of existing capability and service new and existing business cases for geostationary satellite communications. This is an important step in our journey to better connect and protect every corner of the world.”
ENDS
ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.
In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
ABOUT SWISSto12
SWISSto12 is a leading manufacturer of advanced satellite payloads and systems, including the HummingSat: a small yet powerful geostationary telecommunications satellite developed in collaboration with the European Space Agency (ESA) through its public-private-partnership program. The first commercial customer of HummingSat was announced in November 2022. The company’s satellites and payloads benefit from unique and patented 3D-printing technologies and associated Radio Frequency (RF) product designs that deliver lightweight, compact, highly performing, and competitive RF functionality. Besides its space portfolio, the company is also active in telecommunications, surveillance and radar applications for the aeronautic industry. SWISSto12 has developed commercially with success in Europe, the USA and Israel and is amongst the fastest growing aerospace companies in Europe. SWISSto12 spun off in 2011 from the Swiss Federal Institute of Technology in Lausanne (EPFL), is privately owned and backed by prominent Swiss and European Investors.
For further information, visit https://swissto12.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005018/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom